Diseases of the Retina Practice Questions

Q: Which diagnostic test is the most sensitive for detecting early diabetic macular edema?

Optical coherence tomography. ***Optical coherence tomography*** - **Optical coherence tomography (OCT)** is considered the gold standard for detecting and quantifying **macular edema** due to its ability to provide high-resolution, cross-sectional imaging of the retina. - It can visualize and measure **intraretinal and subretinal fluid**, as well as monitor treatment response. - OCT has the highest sensitivity for detecting **early diabetic macular edema** before it becomes clinically apparent on fundoscopy. *Fluorescein angiography* - While useful for detecting **leakage from microaneurysms** and identifying areas of **ischemia**, it primarily provides information about vascular integrity rather than quantifying edema directly. - It is an invasive procedure and does not offer the same detailed anatomical resolution of retinal layers as OCT. - Better suited for assessing capillary non-perfusion and neovascularization. *Ultrasound B-scan* - This test is typically used for imaging the posterior segment when ocular media opacities (e.g., **dense cataracts**, **vitreous hemorrhage**) preclude direct visualization. - It has a much lower resolution compared to OCT and is not precise enough to detect subtle or early **macular edema**. - Primarily used for detecting gross structural abnormalities like retinal detachment or intraocular masses. *Visual field testing* - **Visual field testing** assesses the extent of a person's peripheral and central vision, which is more relevant for conditions like **glaucoma** or **optic nerve damage**. - It can detect functional visual loss but does not directly visualize or quantify **macular edema**. - Changes in central vision may occur with advanced DME, but this is a functional test, not a diagnostic imaging modality for detecting anatomical changes.

Q: A diabetic patient presents with blurred vision. Fundoscopy reveals microaneurysms, dot-blot hemorrhages, and hard exudates in the macular region. OCT confirms center-involving diabetic macular edema. What is the most appropriate next step in management?

Intravitreal anti-VEGF injection. ***Intravitreal anti-VEGF injection*** - **Diabetic macular edema (DME)**, especially when center-involving, is primarily treated with **intravitreal anti-VEGF injections** to reduce vascular leakage and swelling. - This therapy aims to improve or stabilize vision by targeting the underlying pathophysiology of increased vascular permeability in DME. *Panretinal photocoagulation* - This treatment is primarily used for **proliferative diabetic retinopathy (PDR)** to ablate ischemic peripheral retina and prevent neovascularization. - It is not the first-line treatment for **center-involving DME**, where the goal is to reduce macular swelling and improve vision. *Focal laser treatment* - **Focal laser** can be used for **clinically significant macular edema** but is less effective for **center-involving DME** compared to anti-VEGF agents, particularly when the edema is diffuse. - It targets specific leaking microaneurysms, but its role has largely been supplanted by anti-VEGF for widespread macular edema. *Vitrectomy* - **Vitrectomy** is typically reserved for advanced complications of diabetic retinopathy such as **vitreous hemorrhage** that doesn't clear, **tractional retinal detachment**, or severe **epiretinal membranes**. - It is not the primary treatment for **diabetic macular edema**, even when center-involving.

Q: A 60-year-old patient with age-related macular degeneration presents with a sudden onset of central vision loss. Fundoscopy reveals subretinal hemorrhage. What is the recommended treatment?

Intravitreal anti-VEGF injection. ***Intravitreal anti-VEGF injection*** - The sudden onset of **central vision loss** and **subretinal hemorrhage** in a patient with age-related macular degeneration (AMD) indicates **wet AMD**, which is characterized by the growth of abnormal new blood vessels in the choroid (choroidal neovascularization, **CNV**). - **Anti-VEGF agents** (vascular endothelial growth factor inhibitors) are the **first-line treatment** for wet AMD, as they target the underlying angiogenesis and reduce leakage and hemorrhage from these abnormal vessels, thereby preserving or improving vision. *Laser photocoagulation* - **Laser photocoagulation** was historically used for some types of CNV; however, it causes **permanent destruction** of the treated area, leading to a **scotoma** (blind spot) in the visual field. - Its use has been largely superseded by anti-VEGF therapy, especially for lesions involving the **fovea**, due to the significant risk of vision loss. *Intravitreal corticosteroids* - While sometimes used in other retinal conditions with inflammation or edema, **intravitreal corticosteroids** are **not the primary treatment** for wet AMD. - They do not address the fundamental angiogenic process of wet AMD and carry risks such as **cataract formation** and **increased intraocular pressure**. *Observation* - Wet AMD, particularly with **subretinal hemorrhage**, is a **sight-threatening condition** that requires prompt intervention. - **Observation** without treatment would invariably lead to **progressive vision loss** due to ongoing bleeding, fluid leakage, and scarring from the untreated CNV.

Q: Which of the following is a characteristic of retinoblastoma?

Leukocoria. **Leukocoria (White Pupillary Reflex)** - *Correct Answer* - **Leukocoria**, also known as "cat's eye reflex" or white pupillary reflex, is the **most common presenting sign of retinoblastoma** (seen in 50-60% of cases), often first noticed by parents in photographs. - It results from the **tumor mass reflecting light** back through the pupil, creating a characteristic white appearance instead of the normal red reflex. - Other presentations include strabismus, painful red eye with secondary glaucoma, or vision loss. *Buphthalmos* - Incorrect - **Buphthalmos** refers to an abnormally enlarged globe (eyeball), which is the **classic sign of congenital glaucoma**, not retinoblastoma. - While advanced retinoblastomas can rarely cause secondary glaucoma with some globe changes, buphthalmos is not a characteristic or primary presentation. *Hypopyon* - Incorrect - **Hypopyon** is the presence of pus or inflammatory cells in the anterior chamber of the eye, typically seen in severe intraocular inflammation, endophthalmitis, or certain types of uveitis. - Retinoblastoma can rarely present with pseudohypopyon (tumor cells in anterior chamber), but true hypopyon is not a characteristic feature. *Phthisis bulbi* - Incorrect - **Phthisis bulbi** refers to a shrunken, disorganized, non-functional eye resulting from severe trauma, chronic inflammation, or end-stage ocular disease. - This represents severe ocular damage and is not a primary presentation or characteristic of retinoblastoma.

Q: A 45-year-old woman with diabetes presents with worsening vision. Fundoscopy reveals proliferative diabetic retinopathy. Which treatment option has been shown to be effective in reducing the risk of severe vision loss?

Panretinal photocoagulation. ***Panretinal photocoagulation*** - This treatment uses a laser to create burns in the peripheral retina, destroying ischemic tissue and reducing the production of **vascular endothelial growth factor (VEGF)**, thereby preventing new, fragile blood vessel formation and ultimately reducing the risk of severe vision loss in **proliferative diabetic retinopathy (PDR)**. - PRP is the standard of care for severe non-proliferative and proliferative diabetic retinopathy to prevent progression to **vitreous hemorrhage** or **tractional retinal detachment**. - **Note**: Intravitreal anti-VEGF therapy (bevacizumab, ranibizumab, aflibercept) is also highly effective for PDR and may be used as an alternative or adjunct to PRP in current practice. *Focal laser treatment* - **Focal laser photocoagulation** primarily targets specific leaking microaneurysms in the macula to treat **diabetic macular edema (DME)**, which causes central vision loss. - It is not the primary treatment for proliferative retinopathy where new blood vessel growth (neovascularization) is the main concern. *Vitrectomy* - **Vitrectomy** is a surgical procedure performed to remove blood from a **vitreous hemorrhage** or to repair a **tractional retinal detachment** that has already occurred as a complication of advanced proliferative diabetic retinopathy. - While effective for these complications, it is a surgical intervention for existing damage rather than a primary preventative treatment to reduce the risk of initial severe vision loss from developing PDR. *Intravitreal corticosteroids* - **Intravitreal corticosteroids** are typically used to treat **diabetic macular edema (DME)**, especially in cases unresponsive to anti-VEGF therapy. - While they can reduce inflammation and leakage, they are not the primary treatment for preventing the progression of neovascularization in proliferative diabetic retinopathy.

Q: In the context of retinal conditions, what is the primary cause of shifting fluid beneath the retina?

Exudative Retinal detachment. ***Exudative Retinal detachment*** - This condition is characterized by the accumulation of **serous fluid** beneath the retina without a retinal break, causing the retina to detach. The fluid can shift with changes in head position due to gravity, leading to a **"shifting fluid" phenomenon**. - It results from conditions that compromise the **retinal pigment epithelium (RPE)** or choroidal vasculature, such as **choroidal tumors**, **inflammatory diseases**, or **severe hypertension**, leading to leakage of fluid. *Tractional Retinal Detachment* - This type of detachment occurs when **fibrovascular membranes** on the retinal surface contract and pull the neurosensory retina away from the RPE. - The detachment is usually **immobile** or minimally mobile because it is held in place by fibrous adhesions, and therefore, does not typically exhibit shifting fluid. *Rhegmatogenous retinal detachment* - This is the most common type of retinal detachment and occurs due to a **full-thickness break or tear** in the retina, allowing vitreous fluid to pass into the subretinal space. - While fluid is present, the key feature is a retinal break, and the detached retina is typically more fixed by the flow through the break rather than gravitationally shifting. *Retinodialysis* - Retinodialysis is a specific type of **rhegmatogenous retinal detachment** characterized by a **disinsertion of the retina from its ora serrata attachment**, often due to trauma. - Similar to other rhegmatogenous detachments, fluid accumulates in the subretinal space, but the primary cause is the tear/disinsertion, and it doesn't primarily manifest as a shifting fluid characteristic, which is more indicative of exudative causes.

Q: All of the following are causes of exudative retinal detachment except:

Retinopathy of prematurity. ***Retinopathy of prematurity*** - This condition primarily causes retinal detachment through **vitreoretinal traction** due to abnormal vessel proliferation and subsequent fibrosis, classifying it as **tractional retinal detachment**, not exudative. - The abnormal vessel growth in the peripheral retina leads to scarring and contracture, pulling the retina away from the underlying RPE. *Retinopathy of toxemia of pregnancy* - This is an **exudative retinal detachment** involving accumulation of fluid beneath the retina due to choroidal ischemia and impaired integrity of the retinal pigment epithelium. - The systemic hypertension and endothelial dysfunction in preeclampsia/eclampsia lead to choroidal vasculopathy and subsequent fluid leakage into the subretinal space. *Exudative retinopathy of Coats* - This condition is characterized by congenital abnormal retinal telangiectatic vessels that leak fluid and lipids, leading to massive **subretinal exudation** and subsequent retinal detachment. - It is a classic example of **exudative retinal detachment** occurring predominantly in young males with yellowish subretinal exudates. *Sympathetic ophthalmia* - This is a rare bilateral granulomatous panuveitis following penetrating ocular trauma that can lead to diffuse **chorioretinal inflammation** and **exudative retinal detachment**. - The autoimmune inflammation causes fluid leakage from choroidal vessels into the subretinal space, similar to Vogt-Koyanagi-Harada syndrome.

Q: Subretinal haemorrhage at the macula in myopia is known as?

Foster Fuchs spot. ***Foster Fuchs spot*** - This refers to a **subretinal hemorrhage** or **pigmentary change** at the macula due to choroidal neovascularization, a common complication in **pathologic myopia**. - It is a specific clinical sign indicating severe retinal damage and potential vision loss in highly myopic eyes. *Lacquer cracks* - These are **breaks in Bruch's membrane** that appear as fine, yellow-white lines in the fundus. - While they can lead to choroidal neovascularization and hemorrhage in myopic eyes, **lacquer cracks themselves are not the hemorrhage**. *Staphyloma* - A staphyloma is an **outpouching or ectasia of the sclera** (often with choroid and retina) due to thinning and weakening of the scleral wall. - It is a structural abnormality related to high myopia but does not directly describe a subretinal hemorrhage at the macula. *Macular retinoschisis* - This is a **splitting of the retinal layers**, typically in the outer plexiform layer, and is common in high myopia. - It leads to fluid accumulation within the retina, but it is a **separation of retinal layers, not a hemorrhage**.

Q: Vitrectomy should be considered if the vitreous haemorrhage is not absorbed within:

3 months. ***3 months*** - Vitrectomy is typically considered if a **vitreous hemorrhage** does not clear within **3 months** to prevent complications like **retinal detachment** or **hemosiderosis**. - Prolonged vitreous hemorrhage can lead to **fibrous proliferation**, which can cause **tractional retinal detachment**. *1 month* - This period is generally too short to consider surgical intervention unless there are signs of **retinal detachment** or other urgent complications. - Many **vitreous hemorrhages** can spontaneously resolve within this timeframe, especially if they are small. *6 months* - Waiting this long to perform a **vitrectomy** for a persistent **vitreous hemorrhage** would be considered a delay. - This delay could lead to increased risks of **permanent vision loss** due to **hemosiderosis** or the progression of **proliferative vitreoretinopathy**. *2 months* - While closer to the recommended timeline, **2 months** may still be too early to definitively conclude that the hemorrhage will not resolve spontaneously. - However, if there are specific concerns or if the hemorrhage is dense, earlier intervention might be considered.

Question 1

A patient presents with a sudden onset of flashes of light and a curtain falling over his vision. Fundoscopy reveals a retinal detachment. What is the most appropriate next step in management?

Accepted Answer

Vitrectomy

Answer

Laser photocoagulation

Answer

Cryopexy

Answer

Pneumatic retinopexy

Question 2

Which diagnostic test is the most sensitive for detecting early diabetic macular edema?

Accepted Answer

Optical coherence tomography

Answer

Fluorescein angiography

Answer

Ultrasound B-scan

Answer

Visual field testing

Question 3

A diabetic patient presents with blurred vision. Fundoscopy reveals microaneurysms, dot-blot hemorrhages, and hard exudates in the macular region. OCT confirms center-involving diabetic macular edema. What is the most appropriate next step in management?

Accepted Answer

Intravitreal anti-VEGF injection

Answer

Panretinal photocoagulation

Answer

Focal laser treatment

Answer

Vitrectomy

Question 4

A 60-year-old patient with age-related macular degeneration presents with a sudden onset of central vision loss. Fundoscopy reveals subretinal hemorrhage. What is the recommended treatment?

Accepted Answer

Intravitreal anti-VEGF injection

Answer

Laser photocoagulation

Answer

Intravitreal corticosteroids

Answer

Observation

Question 5

Which of the following is a characteristic of retinoblastoma?

Accepted Answer

Leukocoria

Answer

Buphthalmos

Answer

Hypopyon

Answer

Phthisis bulbi

Question 6

A 45-year-old woman with diabetes presents with worsening vision. Fundoscopy reveals proliferative diabetic retinopathy. Which treatment option has been shown to be effective in reducing the risk of severe vision loss?

Accepted Answer

Panretinal photocoagulation

Answer

Focal laser treatment

Answer

Vitrectomy

Answer

Intravitreal corticosteroids

Question 7

In the context of retinal conditions, what is the primary cause of shifting fluid beneath the retina?

Accepted Answer

Exudative Retinal detachment

Answer

Tractional Retinal Detachment

Answer

Rhegmatogenous retinal detachment

Answer

Retinodialysis

Question 8

All of the following are causes of exudative retinal detachment except:

Accepted Answer

Retinopathy of prematurity

Answer

Retinopathy of toxemia of pregnancy

Answer

Sympathetic ophthalmia

Answer

Exudative retinopathy of Coats

Question 9

Subretinal haemorrhage at the macula in myopia is known as?

Accepted Answer

Foster Fuchs spot

Answer

Lacquer cracks

Answer

Staphyloma

Answer

Macular retinoschisis

Question 10

Vitrectomy should be considered if the vitreous haemorrhage is not absorbed within:

Accepted Answer

3 months

Answer

1 month

Answer

6 months

Answer

2 months

Diseases of the Retina — MCQs

Diseases of the Retina — MCQs

On this page

Practice by Chapter

Want unlimited practice?